DOCSLIB.ORG

Health Products Regulatory Authority 08 March 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Products Regulatory Authority 08 March 2019 HealthProductsRegulatoryAuthority IPAR Publicly Available Assessment Report for a Veterinary Medicinal Product FasimecDuo50mg/ml+1mg/mloralsuspensionforsheep 08March2019 CRN000XGK Page1of10 HealthProductsRegulatoryAuthority PRODUCT SUMMARY EU Procedure Number IE/V/0493/001(formerlyUK/V/0428/001) Name, Strength, Pharmaceutical Form FasimecDuo50mg/ml+1mg/mloralsuspensionforsheep Active Substances(s) Triclabendazole,Ivermectin ElancoGmbH,Heinz-Lohmann-Strasse4,27472Cuxhaven, Applicant Germany Fixedcombinationapplication(Article13bofDirectiveNo Legal Basis of Application 2001/82/EC) Target Species Sheep Treatmentofmixedtrematode(fluke)andnematodeor arthropodinfectionsduetogastrointestinalroundworms, lungworms,liverflukeandnasalbots. Gastrointestinalnematodes(adultandimmature): Haemonchus contortus, Teladorsagia (Ostertagia) circumcincta, Trichostrongylusspp,Cooperiaspp,Nematodirussppincluding N. battus, Strongyloides papillosus,Oesophagostomumspp,and adultChabertia ovina. Inhibitedlarvalstagesandbenzimidazoleresistantstrainsof Indication For Use Haemonchus contortusandTeladorsagia (Ostertagia) circumcinctaarealsocontrolled. Liverfluke(mature,immatureandearlyimmaturestagesdown tolessthan1weekofage): Fasciola hepatica Lungworms(adultandimmature): Dictyocaulus filaria Nasalbots(allstages): Oestrus ovis ATC Code QP54AA51 ​Date of completion of the original mutual recognition ​20April2012 ​Date product first authorised in the Reference Member 20November2007(UK)​ State (MRP only) 19October2012(IE) ​France,Ireland(nowRMS),Italy,Spain Concerned Member States for original procedure​ UKaddedviaRMSchange PUBLIC ASSESSMENT REPORT ThepublicassessmentreportreflectsthescientificconclusionreachedbytheHPRAattheendoftheevaluationprocessand providesasummaryofthegroundsforapprovalofthemarketingauthorisationforthespecificveterinarymedicinalproduct.It ismadeavailablebytheHPRAforinformationtothepublic,afterthedeletionofcommerciallyconfidentialinformation.The legalbasisforitscreationandavailabilityiscontainedinArticle25.4ofECDirective2001/82/ECasamendedbyDirective 2004/28/ECforveterinarymedicinalproducts.Itisaconcisedocumentwhichhighlightsthemainpartsofthedocumentation submittedbytheapplicantandthescientificevaluationcarriedoutbytheHPRAleadingtotheapprovaloftheproductfor marketinginIreland. TheSummaryofProductCharacteristics(SPC)forthisproductisavailableontheHPRA'swebsite. I. SCIENTIFIC OVERVIEW FasimecDuo50mg/ml+1mg/mlOralSuspensionforSheepisanoralsuspensioncontainingtriclabendazole 50 mg/mland ivermectin 1 mg/mlforuseinthetreatmentandcontrolofgastrointestinalnematodes,liverfluke,lungwormsandnasalbotsin sheep. TheproductmayalsobeusedtotreatbendimidazoleresistantHaemonchus contortus andTeladorsagia circumcinta . Therecommendeddoserateis1 mlper5 kgbodyweight.TheproductwasauthorisedNationallyintheUnitedKingdomin November2007. 08March2019 CRN000XGK Page2of10 HealthProductsRegulatoryAuthority The product is produced and controlled using validated methods and tests which ensure the consistency of the product releasedonthemarket. Ithasbeenshownthattheproductcanbesafelyusedinthetargetspecies. Theproductissafefor theuser,theconsumeroffoodstuffsfromtreatedanimalsandfortheenvironment,whenusedasrecommended. Suitable warningsandprecautionsareindicatedintheSPC.[1] Theefficacyoftheproductwasdemonstratedaccordingtotheclaims madeintheSPC. Theoverallbenefit/riskanalysisisinfavourofgrantingamarketingauthorisation. II. QUALITY ASPECTS A. Composition Theproductcontainsivermectin1mg/mlandtriclabendazole50mg/ml,andexcipientsmethylparahydroxybenzoate(E218), propylparahydroxybenzoate(E216),benzylalcohol,microcrystallinecelluloseandcarmellosesodium,povidoneK30,propylene glycol,disodiumphosphatedodecahydrateandpurifiedwater.Thechoiceoftheformulationandpresenceofpreservativeare justified. Theproductispresentedinwhitehighdensitypolyethylene(HDPE)bottlesofnominalcapacity0.8,2.2,5.0litres,anda12.0 litreHDPEcontainer.Bluepolypropylenescrewcapswithaflip-topareusedasclosuresforthesmallerpacksizes;ablueHDPE screwcapisusedonthe12 litrepack. Theproductisanestablishedpharmaceuticalformanditsdevelopmentisadequatelydescribedinaccordancewiththe relevantEuropeanguidelines. B. Method of Preparation of the Product Theproductismanufacturedfullyinaccordancewiththeprinciplesofgoodmanufacturingpracticefromalicensed manufacturingsite. Themanufactureofabatchoftheproducthasbeendescribed. In-processchecksareconductedfor completenessofdissolutionofsolublesubstances,forabsenceoffoamingthatmightselectivelyremovesuspendedmaterials fromthebulk,andforhomogeneity,freedomfromaggregatesandviscosityincreaseinthefinalstages. Filledcontainersare check-weighed,withlimitsreflecting100 - 103 %oftheclaimedcontent. Processvalidationdataontheproducthavebeen presentedinaccordancewiththerelevantEuropeanguidelines. C. Control of Starting Materials TheactivesubstanceivermectinisanestablishedactivesubstancedescribedintheEuropeanPharmacopoeia(Ph. Eur.) Acopy ofthecurrentEDQMcertificateofsuitabilityhasbeenprovided. Notestingadditionaltothatspecifiedinthemonographof theEuropeanPharmacopoeiaiscarriedout. Nopharmacopoeialspecificationisavailablefortriclabendazole,forwhichanin-housespecificationhasbeendeveloped. The agreedspecificationhasbeenprovided. Dispersiblecellulose,anintimatemixtureofmicrocrystallinecelluloseandcarmellosesodium,isthesubjectofamonographin theBritishPharmacopoeia. AllothersubstancesaredescribedintheEuropeanPharmacopoeia. Thespecificationsappliedare appropriatelythoseoftherelevantmonograph. Thedossierincludesacertificateofanalysisforonebatchofeachingredient, showingcompliance. D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies TherearenosubstanceswithinthescopeoftheTSEGuidelinepresentorusedinthemanufactureofthisproduct. E. Control on intermediate products Therearenointermediateproducts.Thesuspensionisnotstoredortransportedinbulk. F. Control Tests on the Finished Product Thefinishedproductspecificationcontrolstherelevantparametersforthepharmaceuticalform. Thetestsinthespecification, andtheirlimits,havebeenjustifiedandareconsideredappropriatetoadequatelycontrolthequalityoftheproduct. Satisfactoryvalidationdatafortheanalyticalmethodshavebeenprovided. Batchanalyticaldatafromtheproposed productionsitehavebeenprovideddemonstratingcompliancewiththespecification.Testsincludethoseforappearance,pH, density,andresuspendability. G. Stability The Certificate of Suitability for ivermectin specifies a 3 year retest interval for material stored in the commercial container, double-linedpolyethylenebagswithinanaluminiumdrum. The dossier includes a report on stability tests carried out on three batches of triclabendazole. These have been stored in containers representative of commercial packaging for 12 months under VICH accelerated conditions, 40°C/75%RH, and for 36 monthsunderbothlong-termconditions,25°C/60%RH,andrefrigeration,5°C. Samplesweretestedandonthebasisofthe evidence,theproposedretestintervalof5 yearsisjustified. Nospecialconditionsofstoragearerequired. 08March2019 CRN000XGK Page3of10 HealthProductsRegulatoryAuthority StabilitydataonthreebatchesthefinishedproducthasbeenprovidedinaccordancewithapplicableEuropeanguidelines, demonstratingthestabilityoftheactivesubstancewhenstoredundertheapprovedconditions.Testsincludethosefor appearance,density,resuspendability,pHandmicrobialpurity. J. Other Information Theshelflifeoftheveterinarymedicinalproductaspackagedforsaleis18months.Afterfirstopeningtheimmediate packaging,theshelf-lifeis12months.Theproductshouldbestoredintheclosedoriginalcontainer. III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL) Bothactivesubstances,triclabendazoleandivermectin,arewellknownandwellestablishedsubstancesthathavebeenusedin veterinary medicine for a number of years. This is a full stand alone fixed combination product for sheep which is an oral flukicideandbroadspectrumantiparasiticdrench. Fasimec Duo S 0.1%/5% Oral Suspension for Sheep is a white to cream-coloured oral suspension containing 5% triclabendazoleand0.1%ivermectin. Itisadministeredorallyatadoserateof2 ml/10 kg bodyweight(bw)whichisequivalent to 0.2 mg ivermectin and 10 mg triclabendazole per kg bw. The administration may be repeated depending on the epidemiologicalsituation. III.A Safety Testing Pharmacological Studies Pharmacology: Triclabendazole: Triclabendazoleisamemberofthesulphidebenzimidazolegroupofanthelmintics. Itismetabolisedinhostanimalsbyafirst passprocesstoasulphoxidewhichisthoughttohaveanthelminticactivityandissubsequentlymetabolisedtoasulphone, whichisthoughttobeanthelminticallyactiveaswell. Ivermectin: Ivermectinisanavermectin. Ithasabroadspectrumofactivityagainstnematodeandarthropodspeciesinmanydomestic animalsandisusedinmanforthetreatmentofOnchocerca volvulus. Pharmacodynamics: Triclabendazole: Thetriclabendazolemodeofactionisnotfullyclearbutisthoughttointerferewithintracellulartransportmechanismsand inhibitproteinsynthesis. ItisactiveagainsttheliverflukeFasciola hepatica. Ivermectin: Ivermectin is a member of the macrocyclic lactone class. These substances bind selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeabilityofthecellmembranetochlorideionswithhyperpolarisationofthenerveormusclecell,resultinginparalysisand deathoftheparasite. Mammalsdonothaveglutamate-gatedchloridechannels;themacrocycliclactoneshavealowaffinity forothermammalianligand-gatedchannelsanddonotreadilycrosstheblood-brainbarrier. Pharmacokinetics: Ivermectin:
Load more

Recommended publications
  • Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels
    DISEASES OF AQUATIC ORGANISMS Published October 4 Dis. aquat. Org. l Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels ' Department of Fish Diseases, Royal Veterinary and Agricultural University, 13 Biilowsvej, DK-1870 Frederiksberg C, Denmark Department of Pharmacy, Royal Veterinary and Agricultural University, 13 Biilowsvej. DK-1870 Frederiksberg C,Denmark ABSTRACT: The antiparasitic efficacies of 9 benzimidazoles in commercially avalable formulations were tested (water bath treatments) on small pigmented eels Anguilla anguilla, expenmentally infected by 30 to 140 specimens of Pseudodactylogyrus spp. (Monogenea).Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg 1-') eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100 % effective only at a concen- tration of 10 mg I-'. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Lodltac) (10 mg l-') caused a reduction of the infection level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac).Thiabendazole (Equizole), even at a concentration as high as 100 mg l-', was without effect on Pseudodactylogyrus spp. INTRODUCTION range of commercially available benzimidazole com- pounds. If drug resistance will develop under practical The broad spectrum anthelmintic drug mebendazoIe eel-farm conditions in the future, it is likely to be was reported as an efficacious compound against infes- recognized during treatments with commercially avail- tations of the European eel Anguilla anguilla with gill able drug formulations. Therefore this type of drug parasitic monogeneans of the genus Pseudodactylo- preparations were used in the present study. gyms (Szekely & Molnar 1987, Buchmann & Bjerre- gaard 1989, 1990, Mellergaard 1989).
    [Show full text]
  • Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans
    S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N.
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Egg Hatch Test a Useful Tool for Albendazole Resistance Diagnosis
    Veterinary Parasitology 271 (2019) 7–13 Contents lists available at ScienceDirect Veterinary Parasitology journal homepage: www.elsevier.com/locate/vetpar Research paper The egg hatch test: A useful tool for albendazole resistance diagnosis in T Fasciola hepatica Laura Ceballosa, Candela Cantona, Cesar Pruzzob, Rodrigo Sanabriab,c, Laura Morenoa, ⁎ Jaime Sanchisd, Gonzalo Suareze, Pedro Ortizf, Ian Fairweatherg, Carlos Lanussea, Luis Alvareza, , María Martinez-Valladaresh a Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), UNCPBA-CICPBA-CONICET, Facultad de Ciencias Veterinarias, Campus Universitario, Tandil, Argentina b Facultad de Ciencias Veterinarias, Universidad Nacional de la Plata (UNLP), La Plata, Argentina c INTECH, CONICET-UNSAM, Chascomus, Argentina d Departamento de Parasitología, Universidad de la República (Regional Norte), Salto, Uruguay e Área Farmacología, Facultad de Veterinaria, Universidad de la República (UDELAR), Montevideo, Uruguay f Facultad de Ciencias Veterinarias, Universidad Nacional de Cajamarca (UNC), Cajamarca, Peru g School of Biological Sciences, The Queen´s University of Belfast, Belfast, Northern Ireland, United Kingdom h Instituto de Ganadería de Montaña (CSIC-Universidad de León), Department of Animal Health, Grulleros, León, Spain ARTICLE INFO ABSTRACT Keywords: In the current study, the egg hatch test (EHT) has been evaluated as an in vitro technique to detect albendazole Fasciola hepatica (ABZ) resistance in Fasciola hepatica. The intra- and inter-assay variations of the EHT were measured by means of Albendazole the coefficient of variation in different fluke isolates and over time; then, the results of the EHT werecompared Resistance with the “gold standard” controlled efficacy test, which assesses the in vivo anthelmintic efficacy. The EHT was Egg hatch test used later to evaluate the intra-herd variability regarding the level of ABZ resistance in calves infected by the same fluke isolate.
    [Show full text]
  • Praziquantel Treatment in Trematode and Cestode Infections: an Update
    Review Article Infection & http://dx.doi.org/10.3947/ic.2013.45.1.32 Infect Chemother 2013;45(1):32-43 Chemotherapy pISSN 2093-2340 · eISSN 2092-6448 Praziquantel Treatment in Trematode and Cestode Infections: An Update Jong-Yil Chai Department of Parasitology and Tropical Medicine, Seoul National University College of Medicine, Seoul, Korea Status and emerging issues in the use of praziquantel for treatment of human trematode and cestode infections are briefly reviewed. Since praziquantel was first introduced as a broadspectrum anthelmintic in 1975, innumerable articles describ- ing its successful use in the treatment of the majority of human-infecting trematodes and cestodes have been published. The target trematode and cestode diseases include schistosomiasis, clonorchiasis and opisthorchiasis, paragonimiasis, het- erophyidiasis, echinostomiasis, fasciolopsiasis, neodiplostomiasis, gymnophalloidiasis, taeniases, diphyllobothriasis, hyme- nolepiasis, and cysticercosis. However, Fasciola hepatica and Fasciola gigantica infections are refractory to praziquantel, for which triclabendazole, an alternative drug, is necessary. In addition, larval cestode infections, particularly hydatid disease and sparganosis, are not successfully treated by praziquantel. The precise mechanism of action of praziquantel is still poorly understood. There are also emerging problems with praziquantel treatment, which include the appearance of drug resis- tance in the treatment of Schistosoma mansoni and possibly Schistosoma japonicum, along with allergic or hypersensitivity
    [Show full text]
  • TRICLABENDAZOLE First Draft Prepared by Philip T. Reeves, Canberra, Australia and Gerald E. Swan, Pretoria, South Africa Addendu
    TRICLABENDAZOLE First draft prepared by Philip T. Reeves, Canberra, Australia and Gerald E. Swan, Pretoria, South Africa Addendum to the monographs prepared by the 40th and 66th meetings of the Committee and published in FAO Food & Nutrition Paper 41/5 and FAO JECFA Monographs 2, respectively. IDENTITY Chemical name: 5-Chloro-6-(2,3-dichlorophenoxy)-2-methylthio-1H-benzimidazole {International Union of Pure and Applied Chemistry name} Chemical Abstracts Service (CAS) number: 68786-66-3 Synonyms: Triclabendazole (common name); CGA 89317, CGP 23030; proprietary names Fasinex®, Soforen®, Endex®, Combinex®, Parsifal®, Fasimec®, Genesis®, GenesisTM Ultra. Structural formula: H Cl N S Cl O N CH3 Cl Molecular formula: C14H9Cl3N2OS Molecular weight: 359.66 OTHER INFORMATION ON IDENTITY AND PROPERTIES Pure active ingredients: Triclabendazole Appearance: White crystalline solid Melting point: 175-176oC (Merck), α-modification; 162oC, β-modification Solubility: Soluble in tetrahydrofuran, cyclohexanone, acetone, iso-propanol, n- octanol, methanol; slightly soluble in dichloromethane, chloroform, toluene, xylene, ethyl acetate; insoluble in water, hexane. RESIDUES IN FOOD AND THEIR EVALUATION The Joint FAO/WHO Expert Committee on Food Additives (JECFA) reviewed triclabendazole at its 40th and 66th meetings (FAO/WHO, 1993, 2006). At the 40th meeting the Committee established an ADI of 0-3 μg/kg of bodyweight (0-180 μg per day for a person of 60 kg bodyweight) and recommended the following Maximum Residue Limits (µg/kg): 2 MRLs recommended by the 40th
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers As Repurposed Drug Candidates in Cancer Therapy
    pharmaceuticals Article Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy Rosalba Florio 1, Simone Carradori 1,* , Serena Veschi 1 , Davide Brocco 1, Teresa Di Genni 1, Roberto Cirilli 2 , Adriano Casulli 3,4 , Alessandro Cama 1,5,* and Laura De Lellis 1 1 Department of Pharmacy, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy; rosalba.fl[email protected] (R.F.); [email protected] (S.V.); [email protected] (D.B.); [email protected] (T.D.G.); [email protected] (L.D.L.) 2 Centro Nazionale per il Controllo e la Valutazione dei Farmaci, Istituto Superiore di Sanità, 00161 Rome, Italy; [email protected] 3 WHO Collaborating Centre for the Epidemiology, Detection and Control of Cystic and Alveolar Echinococcosis (in Animals and Humans), Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; [email protected] 4 European Union Reference Laboratory for Parasites, Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy 5 Center for Advanced Studies and Technology, University “G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy * Correspondence: [email protected] (S.C.); [email protected] (A.C.) Citation: Florio, R.; Carradori, S.; Abstract: Repurposing of approved non-antitumor drugs represents a promising and affordable Veschi, S.; Brocco, D.; Di Genni, T.; strategy that may help to increase the repertoire of effective anticancer drugs. Benzimidazole-based Cirilli, R.; Casulli, A.; Cama, A.; De anthelmintics are antiparasitic drugs commonly employed both in human and veterinary medicine. Lellis, L. Screening of Benzimidazole- Benzimidazole compounds are being considered for drug repurposing due to antitumor activities Based Anthelmintics and Their displayed by some members of the family.
    [Show full text]
  • 2.Anthelmintics
    Anthelmintic Anthelmintic or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. They may also be called vermifuges (those that stun) or vermicides (those that kill). Anthelmintics are used to treat people who are infected by helminths, a condition called helminthiasis. These drugs are also used to treat infected animals. Antiparasitics that specifically target worms of the genus Ascaris are called ascaricides. Classification: Benzimidazoles: Albendazole – effective against threadworms, roundworms, whipworms, tapeworms, hookworms Mebendazole – effective against various nematodes Thiabendazole – effective against various nematodes Fenbendazole – effective against various parasites Triclabendazole – effective against liver flukes Flubendazole – effective against most intestinal parasites Abamectin (and by extension ivermectin) - effective against most common intestinal worms, except tapeworms, for which praziquantel is commonly used in conjunction for mass dewormings Diethylcarbamazine – effective against Wuchereria bancrofti, Brugia malayi, Brugia timori, and Loa loa. Pyrantel pamoate – effective against most nematode infections residing within the intestines `Levamisole Salicylanilide – mitochondrial un-couplers (used only for flatworm infections): Niclosamide Oxyclozanide Nitazoxanide – readily kills Ascaris lumbricoides,[5] and also possess antiprotozoal effects[6]
    [Show full text]
  • Report of the WHO Informal Meeting on Use of Triclabendazole in Fascioliasis Control
    Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control WHO headquarters, Geneva, Switzerland 17–18 October 2006 WHO/CDS/NTD/PCT/2007.1 Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control WHO headquarters, Geneva, Switzerland 17–18 October 2006 © World Health Organization 2007 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
    [Show full text]